Catalog No.: PC-21596Not For Human Use, Lab Use Only.
Lorpucitinib (JNJ-64251330) is potent, selective and orally bioavailable pan-JAK inhibitor with IC50 of 0.37/8.6/92/7.4 nM for JAK1/JAK2/JAK3/Tyk2 respectively.
Lorpucitinib (JNJ-64251330) is potent, selective and orally bioavailable pan-JAK inhibitor with IC50 of 0.37/8.6/92/7.4 nM for JAK1/JAK2/JAK3/Tyk2 respectively.
Lorpucitinib (JNJ-64251330) shows comparable potency to tofacitinib in an IFNα-stimulated STAT4 (54 nM and 31 nM, respectively) and an IL-12-stimulated STAT4 (257 nM and 440 nM, respectively) assay.
Lorpucitinib (JNJ-64251330) is 5-6 fold less potent in GM-CSF-stimulated pSTAT5 (303 nM and 51 nM, respectively) and IL-2-stimulated pSTAT5 (61 nM and 12 nM, respectively) assays.
Lorpucitinib (JNJ-64251330) is a GI tract-restricted JAK inhibitor that selectively inhibited cytokine responses in colonic tissue and not in plasma.
